XML 104 R84.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Segment and Geographic Information Segment and Geographic Information (Details) - USD ($) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2015 | Sep. 30, 2015 | Jun. 30, 2015 | Mar. 31, 2015 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure |  |  |  |  |  |  |  |  |  | $ 98,919 |  |  |  |  |
Asset impairments |  |  |  |  |  |  |  |  |  | 1,217,000 |  | $ 253,560,000 |  | $ 0 |
Asset Impairments Charges and Other PP&E Impairment |  |  |  |  |  |  |  |  |  | 1,217,000 |  | 255,116,000 |  | 0 |
Sales to external customers |  |  |  |  |  |  |  |  |  | 859,154,000 |  | 1,040,160,000 |  | 1,192,952,000 |
Depreciation and amortization expense |  |  |  |  |  |  |  |  |  | 37,509,000 |  | 45,448,000 |  | 43,176,000 |
Operating income (loss) (2)(5) |  | $ 2,332,000 | $ 20,064,000 | $ 34,939,000 | $ 37,000 | $ (238,918,000) | $ 15,609,000 | $ 25,129,000 | $ 14,957,000 | 57,372,000 | [1],[2] | (183,223,000) | [3],[4] | 138,157,000 |
Total assets (3) |  | 1,233,082,000 |  |  |  | 1,200,140,000 |  |  |  | 1,233,082,000 |  | 1,200,140,000 |  | 1,459,517,000 |
Capital expenditures |  |  |  |  |  |  |  |  |  | 17,785,000 |  | 47,039,000 |  | 62,135,000 |
Escrow Settlement |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,003,000 |
Segments, Geographical Areas [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Property, plant and equipment, net |  | 251,049,000 |  |  |  | 266,277,000 |  |  |  | 251,049,000 |  | 266,277,000 |  |  |
United States [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 425,985,000 |  | 513,691,000 |  | 560,846,000 |
Segments, Geographical Areas [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Property, plant and equipment, net |  | 145,014,000 |  |  |  | 153,987,000 |  |  |  | 145,014,000 |  | 153,987,000 |  |  |
CZECH REPUBLIC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segments, Geographical Areas [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Property, plant and equipment, net |  | 18,454,000 |  |  |  | 19,742,000 |  |  |  | 18,454,000 |  | 19,742,000 |  |  |
China [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 147,720,000 |  | 109,978,000 |  | 188,047,000 |
Segments, Geographical Areas [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Property, plant and equipment, net |  | 75,409,000 |  |  |  | 79,691,000 |  |  |  | 75,409,000 |  | 79,691,000 |  |  |
Germany [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segments, Geographical Areas [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Property, plant and equipment, net |  | 11,572,000 |  |  |  | 12,246,000 |  |  |  | 11,572,000 |  | 12,246,000 |  |  |
Other Non-U.S. Countries [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 285,449,000 |  | 416,491,000 |  | 444,059,000 |
Segments, Geographical Areas [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Property, plant and equipment, net |  | 600,000 |  |  |  | 611,000 |  |  |  | 600,000 |  | 611,000 |  |  |
Non-U.S. Countries [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 433,169,000 |  | 526,469,000 |  | 632,106,000 |
Segments, Geographical Areas [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Property, plant and equipment, net |  | 106,035,000 |  |  |  | 112,290,000 |  |  |  | 106,035,000 |  | 112,290,000 |  |  |
Energy & Chemicals [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Impairments Charges and Other PP&E Impairment |  |  |  |  |  |  |  |  |  |  |  | 68,796,000 |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 154,249,000 |  | 330,968,000 |  | 388,018,000 |
Depreciation and amortization expense |  |  |  |  |  |  |  |  |  | 9,984,000 |  | 11,805,000 |  | 9,649,000 |
Operating income (loss) (2)(5) |  |  |  |  |  |  |  |  |  | 13,307,000 |  | (10,050,000) |  | 78,006,000 |
Total assets (3) |  | 177,514,000 |  |  |  | 251,810,000 |  |  |  | 177,514,000 |  | 251,810,000 |  | 322,936,000 |
Capital expenditures |  |  |  |  |  |  |  |  |  | 3,316,000 |  | 4,074,000 |  | 24,834,000 |
Energy & Chemicals [Member] | Natural gas processing (including petrochemical) applications [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 105,372,000 |  | 180,909,000 |  | 208,706,000 |
Energy & Chemicals [Member] | Liquefied natural gas applications [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 38,184,000 |  | 136,049,000 |  | 143,870,000 |
Energy & Chemicals [Member] | Industrial gas applications [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 10,693,000 |  | 14,010,000 |  | 35,442,000 |
Distribution & Storage [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Impairments Charges and Other PP&E Impairment |  |  |  |  |  |  |  |  |  | 1,217,000 |  | 2,020,000 |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 497,137,000 |  | 487,557,000 |  | 578,806,000 |
Depreciation and amortization expense |  |  |  |  |  |  |  |  |  | 18,432,000 |  | 18,289,000 |  | 16,749,000 |
Operating income (loss) (2)(5) |  |  |  |  |  |  |  |  |  | 50,435,000 |  | 39,549,000 |  | 82,612,000 |
Total assets (3) |  | 657,599,000 |  |  |  | 689,112,000 |  |  |  | 657,599,000 |  | 689,112,000 |  | 666,451,000 |
Capital expenditures |  |  |  |  |  |  |  |  |  | 11,706,000 |  | 36,835,000 |  | 29,583,000 |
Distribution & Storage [Member] | Liquefied natural gas applications [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 109,806,000 |  | 115,909,000 |  | 209,626,000 |
Distribution & Storage [Member] | Bulk industrial gas applications [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 227,650,000 |  | 203,834,000 |  | 204,214,000 |
Distribution & Storage [Member] | Packaged gas industrial applications [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 159,681,000 |  | 167,814,000 |  | 164,966,000 |
BioMedical [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset Impairments Charges and Other PP&E Impairment |  |  |  |  |  |  |  |  |  |  |  | 184,300,000 |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 207,768,000 |  | 221,635,000 |  | 226,128,000 |
Depreciation and amortization expense |  |  |  |  |  |  |  |  |  | 5,953,000 |  | 12,039,000 |  | 13,842,000 |
Operating income (loss) (2)(5) |  |  |  |  |  |  |  |  |  | 41,967,000 |  | (165,336,000) |  | 25,009,000 | [5]
Total assets (3) |  | 178,747,000 |  |  |  | 224,443,000 |  |  |  | 178,747,000 |  | 224,443,000 |  | 396,320,000 |
Capital expenditures |  |  |  |  |  |  |  |  |  | 2,303,000 |  | 3,849,000 |  | 3,484,000 |
BioMedical [Member] | Respiratory therapy [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 118,926,000 |  | 132,321,000 |  | 141,273,000 |
BioMedical [Member] | Life sciences [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 70,572,000 |  | 64,641,000 |  | 65,948,000 |
BioMedical [Member] | Commercial oxygen generation [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 18,270,000 |  | 24,673,000 |  | 18,907,000 |
Corporate [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales to external customers |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  | 0 |
Depreciation and amortization expense |  |  |  |  |  |  |  |  |  | 3,140,000 |  | 3,315,000 |  | 2,936,000 |
Operating income (loss) (2)(5) |  |  |  |  |  |  |  |  |  | (48,337,000) |  | (47,386,000) |  | (47,470,000) |
Total assets (3) | [6] | $ 219,222,000 |  |  |  | $ 34,775,000 |  |  |  | 219,222,000 |  | 34,775,000 |  | 73,810,000 |
Capital expenditures |  |  |  |  |  |  |  |  |  | 460,000 |  | 2,281,000 |  | $ 4,234,000 |
Cost of Sales [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset impairments |  |  |  |  |  |  |  |  |  |  |  | $ 1,556,000 |  |  |
Cost of Sales [Member] | BioMedical [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain (Loss) Related to Litigation Settlement |  |  |  |  |  |  |  |  |  | 15,145,000 |  |  |  |  |
Selling, General and Administrative Expenses [Member] | BioMedical [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain (Loss) Related to Litigation Settlement |  |  |  |  |  |  |  |  |  | $ 376,000 |  |  |  |  |
[1] | (1) During the third quarter of 2016, the Company recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15,145 and Corporate SG&A expenses by $376, net of associated legal fees recorded in 2016. The 2016 operating income also includes asset impairment charges of $1,217 attributed to D&S.
[2] | The 2016 operating income also includes impairment of goodwill and intangible assets totaling $1,217 as described in Note 3, Asset Impairments, to the consolidated financial statements.
[3] | (1) Includes impairment of goodwill and intangible assets totaling $253,560 as described in Note 3, Asset Impairments, to the consolidated financial statements.
[4] | Includes asset impairment charges of $255,116 for the year ended December 31, 2015, attributed to E&C - $68,796, D&S - $2,020, and BioMedical - $184,300.
[5] | The BioMedical segment’s operating income included recovery of $5,003 increasing operating income for the year ended December 31, 2014 from an escrow settlement for breaches of representations and warranties relating to warranty costs (which are in excess of the settlement amount) for certain product lines acquired from AirSep in 2012.
[6] | Corporate assets consist primarily of cash, cash equivalents, and deferred income taxes.

X
- Definition Asset Impairments Charges and Other PP&E Impairment + References No definition available. + Details
Name: | gtls_AssetImpairmentsChargesandOtherPPEImpairment
Namespace Prefix: | gtls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Escrow Settlement + References No definition available. + Details
Name: | gtls_EscrowSettlement
Namespace Prefix: | gtls_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=68055307&loc=d3e2420-110228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 + Details
Name: | us-gaap_Assets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611 + Details
Name: | us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585 + Details
Name: | us-gaap_DepreciationDepletionAndAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349 + Details
Name: | us-gaap_GainLossRelatedToLitigationSettlement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 + Details
Name: | us-gaap_PropertyPlantAndEquipmentNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentsGeographicalAreasAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_CZ
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_CN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_DE
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=gtls_OtherNonU.S.CountriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=gtls_EnergyChemicalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=gtls_NaturalgasprocessingincludingpetrochemicalapplicationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=gtls_LiquefiednaturalgasapplicationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=gtls_IndustrialgasapplicationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=gtls_DistributionStorageMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=gtls_BulkindustrialgasapplicationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=gtls_PackagedgasindustrialapplicationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=gtls_BiomedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=gtls_RespiratorytherapyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=gtls_LifesciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=gtls_CommercialoxygengenerationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |